$hrow
Harrow's Vevye drug shows strong market share growth and is poised for further gains with upcoming insurance coverage and salesforce expansion. A recent settlement allows for an earlier launch of a biosimilar to Eylea, a significant catalyst.
About $hrow
Harrow, Inc. is a pharmaceutical company focused on the ophthalmic market.
Engagements: [------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [------]
[--] Month: [-------] -70%
[--] Months: [----------] +381%
[--] Year: [----------] +413%
1-Year High: [-------] on 2025-11-07
1-Year Low: [---] on 2025-03-02
Engagements by network (24h): X: [------]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
1-Year High: [---] on 2025-12-20
1-Year Low: [--] on 2025-05-04
Mentions by network (24h): X: [---]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $hrow in the last [--] hours which is down 39% from [---] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-12-20
1-Year Low: [--] on 2025-04-18
The most influential creators that mention $hrow in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Michigan_Value | [--] | [-----] | [--] | [-----] |
| @fj_nextstage | [--] | [-----] | [--] | [-----] |
| @mvcinvesting | [--] | [------] | [--] | [---] |
| @Pharmdca | [--] | [-------] | [--] | [---] |
| @Ron_Trades | [--] | [---] | [--] | [---] |
| @Quality_stocksA | [--] | [------] | [--] | [---] |
| @RebellioMarket | [--] | [-------] | [--] | [---] |
| @TheInvestinGuy | [--] | [---] | [--] | [---] |
| @Fund_Stocks | [--] | [--] | [--] | [---] |
| @sujoy48883 | [--] | [--] | [--] | [--] |
Sentiment: 66%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 66%
Daily Average: 86%
[--] Month: 46% +9%
[--] Months: 46% -46%
[--] Year: 46% -54%
1-Year High: 100% on 2025-02-17
1-Year Low: 31% on 2026-01-19
Most Supportive Themes:
- Positive Mentions and Buy Recommendations: (40%) Multiple users are recommending HROW as a buy or expressing positive sentiment towards the stock, often listing it among other potential investments.
- Analysis and Investment Strategy Discussions: (30%) Posts delve into HROW's business model, financials, and future potential, with some users sharing their investment strategies and portfolio updates that include HROW.
- Stock Performance and Price Targets: (20%) Discussions include HROW's current performance, potential price targets, and observations on its stock price movements, such as being 'under [--] is a easy buy'.
Most Critical Themes:
- Healthcare Sector Sell-off Concerns: (10%) One post notes a general sell-off in the healthcare sector, mentioning HROW among other stocks that might be retesting support levels, suggesting potential downward pressure.
Top $hrow Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"#earnings after the close on Monday November [--] [----] $RGTI $CRWV $BBAI $BYND (this time they mean it) $RKLB $ASTS $PLUG $WULF $OXY $MVST $HROW $ARCT $GEVO $GETY $HIT $CAPR $NRGV $BALY $DSP $EGY $CATX $MYO $INO $RRGB $GRDN $WPRT $REAL $HCAT $FLD $DCGO https://www.earningswhispers.com/calendar https://www.earningswhispers.com/calendar"
X Link @DurhamZach99678 2026-02-15T16:19Z [---] followers, [---] engagements
"$HROW Vevye ramped to 12% share despite tiny salesforce/poor insurance coverage/zero ad budget bc Vevye=best drug. Obviously. Now: Jan '26 Tier [--] coverage June 2x salesforce more coming. Bottom line: Vevye 12% share & ramping hard in a 22% CAGR category; Tier [--] insurance=ASP tailwind. https://twitter.com/i/web/status/2023050232208994440 https://twitter.com/i/web/status/2023050232208994440"
X Link @Michigan_Value 2026-02-15T15:02Z [----] followers, [---] engagements
"$HROW Vevye chart: 1) branded DED category 22% CAGR; 2) Q1 seasonal weakness; 3) Vevye market share ramping. Not on chart: CVS win=ASP also heading higher. No data yet"
X Link @Michigan_Value 2026-02-15T15:02Z [----] followers, [----] engagements
"Whatever the market does this week these are current facts: [--]. $SOFI: FY26 estimates give $0.60 in EPS which is 65% growth on FY25 for 32x NTM PE. Those estimates are also likely on the lower end. [--]. $HROW: EBITDA is set to grow at 86% in the NTM for 18.5x NTM EBITDA. That's an EV/EBITDA/Growth ratio of 4.7x. [--]. $NU: Has the best unit economics of all fintechs globally. Set to hit $0.91 in EPS in FY26 (42% growth for 19x PE). [--]. $TMDX: $200M in EBITDA in FY26 would be 33% growth for 22.5x EBITDA. Not that cheap.but resilient in a market downturn. [--]. $ZETA: Currently we trade at 2.25x EV/Revs"
X Link @MMMTwealth 2026-02-15T13:49Z 64.3K followers, 17.7K engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing